O-28 - Innovations and Updates in Mycology

Co-Author(s)

• MA

  Mickaël Aoun, MD

  Head of the Infectious Diseases
  Institut Jules Bordet
  Brussels, Brussels Hoofdstedelijk Gewest, Belgium

  Disclosure: Amplyx Pharmaceuticals (Scientific Research Study Investigator)
• SB

  Sara Barbat, BSN, RN

  Senior Director Clinical Operations
  Amplyx Pharmaceutical
  San Diego, California

  Disclosure: Amplyx Pharmaceuticals (Employee)
• DB

  Devra Barter, MS

  Emerging Infections Epidemiologist
  Colorado Department of Public Health and Environment
  Denver, Colorado

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AB

  Ana Belen Arauz, MD

  Associate Professor of Medicine
  Medicine
  Hospital Santo Tomas
  Birmingham, Alabama

  Disclosure: Mayne Pharma (Scientific Research Study Investigator)
• RB

  Ronen Ben-Ami, MD

  Head of Infectious Diseases Unit
  Tel Aviv Sourasky Medical Center
  Tel Aviv, Tel Aviv, Israel

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• KB

  Kaitlin Benedict, MPH

  Epidemiologist
  CDC
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Pierre Bulpa, MD

  Professor
  ICU
  Mont-Godinne University Hospital, CHU UCL Namur
  Yvoir, Namur, Belgium

  Disclosure: Amplyx Pharmaceuticals (Scientific Research Study Investigator)
• 

  Tom Chiller, MD, MPHTM

  Chief, Mycotic Diseases Branch
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• BC

  Benjamin Colton, PharmD

  Clinical Pharmacy Specialist
  National Institutes of Health
  Bethesda, Maryland

  Disclosure: Merck (Shareholder)Pfizer (Shareholder)
• LD

  Li Deng, PhD

  Mathematical Statistician
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• GD

  Gordana Derado, PhD

  Statistician
  CDC
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• MF

  Monica Farley, MD

  Professor
  Infectious Diseases
  Emory University
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• EF

  Elise Ferre, PA-C, MPH

  Physician Assistant
  NIAID
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• RF

  Ricard Ferrer, MD, PhD

  Critical Care physician
  Vall d’Hebron University Hospital
  Barcelona, Catalonia, Spain

  Disclosure: Shionogi B.V. (Advisor or Review Panel member)
• JF

  Jill Fischer, MT/ASCP

  Bacteriology Laboratory Specialist
  Minnesota Department of Health
  St. Paul, Minnesota

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AF

  Alexandra Freeman, MD

  Senior clinician
  National Institute of Allergy and Infectious Diseases
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AG

  Anita Gellert, BSN

  Ms
  University of Rochester
  Rochester, New York

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• LH

  Lee Harrison, MD

  Head, Infectious Diseases Epidemiology Research Unit
  University of Pittsburgh
  Pittsburgh, Pennsylvania

  Disclosure: GSK: Consultant; Merck: Consultant; Pfizer: Consultant; Sanofi Pasteur: Consultant
• JH

  Justin Hayes, M.D.

  Assistant Professor, Medicine, Division of Infectious Diseases
  University of Arizona College of Medicine
  Tucson, Arizona

  Disclosure: Mayne Pharma (Grant/Research Support)
• MH

  Michael Hodges, BSc. MD

  Chief Medical Officer
  Amplyx Pharmaceuticals
  San Diego, California

  Disclosure: Amplyx Pharmaceuticals Inc. (Employee)
• BJ

  Brendan Jackson, MD, MPH

  Medical Epidemiologist
  Mycotic Diseases Branch
  Centers for Disease Control and Prevention
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• HJ

  Helen Johnston, MPH

  Emerging Infections Unit Manager
  Colorado Department of Public Health and Environment
  Denver, Colorado

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• BK

  Bart Jan Kullberg, M.D., FRCP, FIDSA

  Professor of Medicine and Infectious Diseases
  Radboud univerity medical center
  Nijmegen, Gelderland, Netherlands

  Disclosure: Amplyx (Advisor or Review Panel member)
• 

  Michail Lionakis, MD, ScD

  Chief, Fungal Pathogenesis Section, Laboratory of Clinical Immunology & Microbiology
  National Institute of Allergy and Infectious Diseases
  Bethesda, Maryland

  Disclosure: Matinas BioPharma (Research Grant or Support)
• RL

  Ruying Lu, n/a

  Senior Director
  Matinas BioPharma Inc.
  Bridgewater, New Jersey

  Disclosure: Matinas BioPharma Inc. (Employee)Matinas BioPharma Inc. (Employee, Shareholder)
• ML

  Meghan Lyman, MD

  Medical Epidemiologist
  Mycotic Diseases Branch
  CDC
  Atlanta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Raphael Mannino, PhD

  Chief Scientific Officer
  Matinas BioPharma, Inc.
  Bridgewater, New Jersey

  Disclosure: Matinas BioPharma Inc. (Employee, Shareholder)
• KM

  Kaytlynn Marceaux, MPH

  research assistant
  Johns Hopkins University
  Baltimore, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• TM

  Theresa Matkovits, Ph.D.

  Chief Development Officer
  Matinas BioPharma
  Bedminster, New Jersey

  Disclosure: Matinas BioPharma (Employee, Shareholder)
• TM

  Todd McCarty, MD

  Assistant Professor
  University of Alabama at Birmingham; Birmingham VA Medical Center
  Birmingham, Alabama

  Disclosure: Amplyx (Scientific Research Study Investigator)Cidara (Scientific Research Study Investigator)
• GM

  Gerald McGwin, M.S., Ph.D.

  Professor
  Epidemiology
  University of Alabama at Birmingham
  Birmingham, Alabama

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• RM

  Rachel McMullen, MS

  Research Assistant
  University of Alabama at Birmingham
  Birmingham, Alabama

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Marisa Miceli, MD, FIDSA

  Associate Professor
  Division of Infectious Diseases
  University of Michigan
  Ann Arbor, Michigan

  Disclosure: SCYNEXIS, Inc. (Advisor or Review Panel member)
• MM

  Mary Moore, MBA

  Research Assistant
  University of Alabama at Birmingham
  Birmingham, Alabama

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• JN

  Joelle Nadle, MPH

  Project Coordinator
  California Emerging Infections Program
  Oakland, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• IO

  Iwonka Oborska, PhD

  Independent consultant
  Amplyx
  Horsham, England, United Kingdom

  Disclosure: Amplyx Pharmaceuticals (Consultant, Independent Contractor)
• IO

  Ilana Oren, MD

  head of transplant infectious diseases
  RHCC
  Kiryat Motzkin, Hefa, Israel

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• BP

  Brittany Pattee, MPH

  Epidemiologist
  Minnesota Department of Health
  St. Paul, Minnesota

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AP

  Alisa Peinhardt, MAIS, BSN

  Program Manager - Infectious Disease Clinical Trials Group
  Division of Infectious Disease
  University of Alabama at Birmingham
  Birmingham, Alabama

  Disclosure: Mycoses Study Group Education and Research Consortium (Consultant)
• EP

  Erin Phipps, DVM, MPH

  Principal Investigator, CDI/MuGSI/Candidemia Surveillance
  New Mexico Emerging Infections Program
  University of New Mexico
  Albuquerque, New Mexico

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• LP

  Laurie Proia, MD

  Assistant Professor
  Rush Medical College
  Chicago, Illinois

  Disclosure: Mayne Pharma (Scientific Research Study Investigator)
• GR

  Galia Rahav, MD

  Head of Infectious Disease Unit
  Infectious Disease Unit
  Sheba Medical Center and Tel Aviv University
  Ramat Gan, HaMerkaz, Israel

  Disclosure: AstraZeneca (Scientific Research Study Investigator)
• WS

  William Schaffner, MD

  Professor of Preventive Medicine
  Vanderbilt University
  Nashville, Tennessee

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• HS

  Haran Schlamm, MD

  Consultant
  Amplyx Inc
  Rancho Santa Fe, California

  Disclosure: Amplyx (Consultant)
• SS

  Sarah Shrum, MPH

  coordinator
  New Mexico Emerging Infectious Program
  Albuquerque, New Mexico

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AS

  Andrej Spec, MD, MSCI

  Assistant Professor
  Washingotn University In St Louis, School of Medicine
  St. Louis, Missouri

  Disclosure: Mayne (Consultant, Grant/Research Support)
• DS

  Doris Swaim, RN, BSN, CCRC

  Nurse protocol coordinator
  NIAID/LIR
  Leidos Biomedical Research
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  George R. Thompson, MD

  Associate Professor of Medicine
  Infectious Diseases
  UC-Davis
  Sacramento, California

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• TT

  Tristan Timbrook, PharmD

  Adjunct Instructor
  University of Utah College of Pharmacy
  Salt Lake City, Utah

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• ET

  Edmund Tramont, MD

  Assoc. Dir Special Projects DCR/NIAID/NIH
  National Institute of Allergy and Infectious Diseases
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• BT

  Brandon Tritle, PharmD, BCIDP

  Clinical Pharmacist
  University of Utah Health
  Salt Lake City, Utah

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• AU

  Amanda Urban, DNP, CRNP

  Nurse Practitioner
  Leidos Biomedical Research
  Bethesda, Maryland

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• 

  Jose Vazquez, MD, FIDSA

  Professor of Medicine
  Internal Medicine
  Medical College of Georgia at Augusta University
  Augusta, Georgia

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.
• PW

  Pamela Wedel, BSc

  Vice President, Clinical Operations
  Clinical Operations
  Amplyx Pharmaceuticals
  La Mesa, California

  Disclosure: Amplyx Pharmaceuticals (Employee)
• AZ

  Alexia Zhang, MPH

  Epidemiologist
  Oregon Public Health Division-Acute and Communicable Disease Prevention
  Portland, Oregon

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

Presenting Author(s)

• 

  Jigar Desai, PhD

  Research Fellow
  Fungal Pathogenesis Section, National Institutes of Allergy and Infectious Diseases, National Institutes of Health
  Bethesda, MD

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Andre Hejazi, BS

  PharmD Student
  University of Utah College of Pharmacy
  Salt Lake City, Utah

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• 

  Peter Pappas, MD

  Professor of Medicine
  Medicine
  University of Alabama at Birmingham
  Birmingham, Alabama

  Disclosure: Amplyx : Advisor or Review Panel member (Status: Ongoing); Astellas : Grant/Research Support (Status: Ongoing), Scientific Research Study Investigator (Status: Ongoing); Cidara : Advisor or Review Panel member (Status: Ongoing), Scientific Research Study Investigator (Status: Ongoing); F2G : Advisor or Review Panel member (Status: Ongoing); Mayne Pharma : Scientific Research Study Investigator; Merck : Grant/Research Support (Status: Ongoing); Scynexis : Consultant (Status: Ongoing), Grant/Research Support (Status: Ongoing)

  Slides Slides and Audio
• 

  Brenda Tesini, MD

  Assistant Professor
  New York Emerging Infections Program University of Rochester
  Rochester, NY

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio
• MT

  Mitsuru Toda, PhD

  Epidemiologist
  Centers for Disease Control and Prevention
  Atlanta, GA

  Disclosure: I do not have any relevant financial / non-financial relationships with any proprietary interests.

  Slides Slides and Audio

Presentations:

• MSG-15: Pharmacokinetic (PK), Adverse Events (AEs), and Tolerability Data from an Open Label Randomized Clinical Trial (RCT) Comparing Oral Suba-itraconazole (SUBA-ITC) to Conventional Itraconazole (C-ITC) for Treatment of Endemic Mycosis (EM)
  Peter G. Pappas, MD – University of Alabama at Birmingham; Andrej Spec, MD, MSCI – Washingotn University In St Louis, School of Medicine; Marisa H. Miceli, MD, FIDSA – University of Michigan; Laurie Proia, MD – Rush Medical College; Ana Belen Arauz, MD – Hospital Santo Tomas; Justin Hayes, M.D. – University of Arizona College of Medicine; Alisa Peinhardt, MAIS, BSN – University of Alabama at Birmingham; Rachel McMullen, MS – University of Alabama at Birmingham; Mary K. Moore, MBA – University of Alabama at Birmingham; Gerald McGwin, M.S., Ph.D. – University of Alabama at Birmingham; George R. Thompson, MD – UC-Davis
• the Efficacy and Safety of Low Dose Trimethoprim-sulfamethoxazole for the Treatment of Pneumocystis Pneumonia: A Systematic Review and Meta-analysis
  Brandon Tritle, PharmD, BCIDP – University of Utah Health; Andre A. Hejazi, BS – University of Utah College of Pharmacy; Tristan Timbrook, PharmD – University of Utah College of Pharmacy
• Antifungal Susceptibility Patterns of Candida Parapsilosis Bloodstream Isolates in the US, 2008-2018
  Brenda L. Tesini, MD – New York Emerging Infections Program University of Rochester; Meghan Lyman, MD – CDC; Brendan R. Jackson, MD, MPH – Centers for Disease Control and Prevention; Anita Gellert, BSN – University of Rochester; William Schaffner, MD – Vanderbilt University; Monica M. Farley, MD – Emory University; Sarah Shrum, MPH – New Mexico Emerging Infectious Program; Erin C. Phipps, DVM, MPH – University of New Mexico; Alexia Y. Zhang, MPH – Oregon Public Health Division-Acute and Communicable Disease Prevention; Brittany Pattee, MPH – Minnesota Department of Health; Jill Fischer, MT/ASCP – Minnesota Department of Health; Helen Johnston, MPH – Colorado Department of Public Health and Environment; Devra Barter, MS – Colorado Department of Public Health and Environment; Lee Harrison, MD – University of Pittsburgh; Kaytlynn Marceaux, MPH – Johns Hopkins University; Joelle Nadle, MPH – California Emerging Infections Program
• Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
  Peter G. Pappas, MD – University of Alabama at Birmingham; Bart Jan Kullberg, M.D., FRCP, FIDSA – Radboud univerity medical center; Jose A. Vazquez, MD, FIDSA – Medical College of Georgia at Augusta University; Ilana Oren, MD – RHCC; Galia Rahav, MD – Sheba Medical Center and Tel Aviv University; Mickaël Aoun, MD – Institut Jules Bordet; Pierre Bulpa, MD – Mont-Godinne University Hospital, CHU UCL Namur; Ronen Ben-Ami, MD – Tel Aviv Sourasky Medical Center; Ricard Ferrer, MD, PhD – Vall d’Hebron University Hospital; Todd P. McCarty, MD – University of Alabama at Birmingham; Birmingham VA Medical Center; George R. Thompson, MD – UC-Davis; Sara Barbat, BSN, RN – Amplyx Pharmaceutical; Pamela Wedel, BSc – Amplyx Pharmaceuticals; Iwonka Oborska, PhD – Amplyx; Haran T. Schlamm, MD – Amplyx Inc; Michael Hodges, BSc. MD – Amplyx Pharmaceuticals
• Fungal Disease Mortality Trends, United States, 1999–2017
  Mitsuru Toda, PhD – Centers for Disease Control and Prevention; Brendan R. Jackson, MD, MPH – Centers for Disease Control and Prevention; Li Deng, PhD – Centers for Disease Control and Prevention; Gordana Derado, PhD – CDC; Tom M. Chiller, MD, MPHTM – Centers for Disease Control and Prevention; Kaitlin Benedict, MPH – CDC
• Efficacy of Cochleated Amphotericin B (CAMB) in Mouse and Human Mucocutaneous Candidiasis
  Jigar V. Desai, PhD – Fungal Pathogenesis Section, National Institutes of Allergy and Infectious Diseases, National Institutes of Health; Amanda Urban, DNP, CRNP – Leidos Biomedical Research; Doris Z. Swaim, RN, BSN, CCRC – Leidos Biomedical Research; Elise Ferre, PA-C, MPH – NIAID; Benjamin Colton, PharmD – National Institutes of Health; Ruying Lu, n/a – Matinas BioPharma Inc.; Theresa Matkovits, Ph.D. – Matinas BioPharma; Raphael J. Mannino, PhD – Matinas BioPharma, Inc.; Edmund Tramont, MD – National Institute of Allergy and Infectious Diseases; Michail Lionakis, MD, ScD – National Institute of Allergy and Infectious Diseases; Alexandra Freeman, MD – National Institute of Allergy and Infectious Diseases